From Oil Risk Premiums to Cancer Vaccines (e2613)

From Oil Risk Premiums to Cancer Vaccines (e2613)

March 25, 2026 · 35 min

About this episode

The episode discusses the latest Cash Flow Memo focusing on energy, technology, and healthcare investments, including oil pricing and cancer therapies.

SHOWNOTES In this episode of Telltales, Mike Nicoletti, Jason Wallace, and Hunt Lawrence unpack the latest Cash Flow Memo across energy, technology, and healthcare. The conversation ranges from Iran-driven oil risk and natural gas pricing to AI infrastructure demand, semiconductor inputs, and the long-term investment case for cancer therapies. [00:00] Energy outlook after the Iran conflict Hunt opens with Exhibit C, explaining why he now sees oil supply tightening slightly versus prior expectations and why a return to something closer to normal in the straits could still leave a durable geopolitical risk premium in crude. [03:24] Why oil may stay higher for longer The team discusses why WTI may average closer to $80 in 2026-2028 rather than revisiting $60, with uncertainty around Iran, damaged infrastructure, and future military escalation all influencing pricing. [05:21] Exhibit A and the US fiscal picture Hunt argues the US remains relatively insulated on national accounts because it produces as much oil as it uses and more gas than it consumes, while still expecting the federal deficit trend to improve gradually. [08:24] Energy equities and capital discipline The discussion…

People in this episode

Hosts: Mike Nicoletti, Jason Wallace, Hunt Lawrence

Topics covered

Keywords

Mentioned in this episode

Organizations: Iran, US, Cash Flow Memo, LNG, WTI, AI, semiconductor, cancer therapies

More episodes of Telltales

Explore listener stats, chart rankings, contacts and more on the Telltales podcast page.